Ticker LaunchLondon · AIM · IPO · LLAI
LungLife AI, Inc.
LungLife AI, Inc. (LLAI) was admitted to AIM on Jul 8, 2021, raising £17M at 176p per share. Its market capitalization at admission was about £45M. Investec acted as nominated adviser, with Investec (Sole Bookrunner, Nominated Adviser and Corporate Broker) as broker.
LungLife AI develops clinical diagnostic solutions for the early detection of lung cancer, using a minimally invasive blood test (LungLB) that combines rare cell recovery and blood biomarkers with machine learning.
- Type
- IPO
- Market
- AIM
- Ticker (TIDM)
- LLAI
- Admitted
- Jul 8, 2021
- Offer price
- 176p
- Raised
- £17M
- Market cap at admission
- £45M
- Nominated adviser
- Investec
- Brokers
- Investec (Sole Bookrunner, Nominated Adviser and Corporate Broker)
- Sector
- Biotech & pharma
- Country
- United States (Delaware Inc.; operations in California and UK)
More on this listing for subscribers
- New money versus sale shares
- Shares in issue at admission
- Free float
- ISIN
- Source announcements
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Sources
From company announcements filed with the FCA's National Storage Mechanism. Subscribers see the list of announcements for each listing.
Other London listings around the same time
- LendInvest PlcAIM · Jul 14, 2021
- Seraphim Space Investment Trust plcMain Market · Jul 14, 2021
- CMO Group plcAIM · Jul 8, 2021
- Saietta Group plcAIM · Jul 7, 2021
- Wise plcMain Market · Jul 7, 2021
- Baltic Classifieds Group PLCMain Market · Jul 5, 2021